ClinicalTrials.gg
Active, not recruitingNCT06734234Updated Jul 30, 2026

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

A Phase 1 interventional study of GSK4771261 and Placebo matching GSK4771261 in Kidney Disease, sponsored by GlaxoSmithKline. Active, not recruiting at 23 sites in 8 countries. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.

Primary conditionPolycystic Kidney, Autosomal DominantRegistry: Kidney DiseasesReclassifiedWhy we changed it
Registry
Kidney Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Polycystic Kidney, Autosomal Dominant
Why
  1. The study's title name Polycystic Kidney, Autosomal Dominant, a narrower term within Kidney Diseases.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Polycystic Kidney, Autosomal Dominant with a site in Spain — 3 open to participants now, 6 under way, 2 of them phase 3. Polycystic Kidney, Autosomal Dominant · Spain.

Planned enrollment
10th of 14
86 · median 255
Started
2024
with 2 others
Phase 1
Only one
of the 18
Registered
15th of 18
by date
Lead sponsor
1 of 18
GlaxoSmithKline

Among the 18 studies in Polycystic Kidney, Autosomal Dominant with a site in Spain, this one is the 10th largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2024, is the only one in phase 1, and was the 15th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

3 of the 18 studies in Polycystic Kidney, Autosomal Dominant with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Polycystic Kidney, Autosomal Dominant with a site in Spain, or all of them as a file.
02

Study summary

This is a study where a new drug, called GSK4771261 is being tested. Neither the study doctors, study staff or participants will be aware of what treatment is being given. Part A is testing the new study treatment on healthy people. This is to see if it's safe, what it does to the body, and how the body's defense system responds to it. Part B is similar, but the study treatment will be given to people who have a kidney disease called autosomal dominant polycystic kidney disease (ADPKD).

03

Conditions studied

  • Kidney Disease

Browse trials for

Keywords

  • Phase 1
  • GSK4771261
  • Autosomal dominant polycystic kidney disease (ADPKD)
  • Safety
  • Tolerability
  • Pharmacokinetics
  • Pharmacodynamics
  • Immunogenicity
04

In context

Polycystic Kidney, Autosomal Dominant Reclassified

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

This study's planned enrollment of 86 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.

Browse Polycystic Kidney, Autosomal Dominant studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Polycystic Kidney, Autosomal Dominant, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Kidney Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Part A

  • Body weight greater than or equal to (>=) 45 kilograms (kg) and basal metabolic index () within the range 19.5 to 32 kilograms per square meters (kg/m\^2), inclusive
  • Capable of giving signed ,
  • Participants who are overtly healthy as determined by medical evaluation by the investigator or a medically qualified designee based on medical history, physical examination, laboratory tests, and cardiac monitoring
  • Women must be of non-

For Part B (planned Cohorts 1-3 and optional cohorts 4-5):

  • Body weight >=45 kg and BMI within the range 19.5 to 32 kg/m\^2, inclusive.
  • Capable of giving signed informed consent, Confirmed diagnosis of Autosomal dominant polycystic kidney disease (ADPKD) by either applicable guidelines and/or genetic and imaging screening assessments
  • Participants diagnosed with ADPKD may have complications or comorbidities directly related to ADPKD but should be otherwise healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests clinical testing
  • Confirmation of known ADPKD causal genetic mutation(s) at the Polycystic kidney disease (PKD)1 and/or PKD2 loci based on genetic testing at screening and/or existing genetic information collected during the participant's routine clinical care for ADPKD from a genetic testing provider that, in the judgement of the investigator, is clinically valid.
  • Mayo imaging classification groups 1C, 1D or 1E as assessed using the information collected at screening
  • Estimated (eGFR) greater than or equal to (>=) 45 milliliters per minutes per 1.73 square meters (mL/min/1.73m\^2) (based on the Chronic kidney disease- Epidemiology Collaboration [CKD-EPI 2021] eGFR equation) and is not anticipated by the participant's regular treating physician to have a sustained decline by greater than (>)10 percent (%) over the following 12 months
  • Intolerant of tolvaptan treatment, unwilling to initiate tolvaptan treatment or ineligible for tolvaptan treatment for ADPKD
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and agrees to use methods as discussed with the study doctor.
  • Woman of childbearing potential (WOCBP) and Woman of non-childbearing potential (WONCBP) must have a negative highly sensitive pregnancy test prior to the Magnetic resonance imaging (MRI) scan being performed in the screening period of Part B
  • A WOCBP and WONCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention For Part B (additional inclusion criteria for optional cohorts 4-5 only)
  • eGFR >=30 mL/min/1.73m\^2 (based on the CKD-EPI 2021 eGFR equation) and, in the clinical judgement of the investigator, the participant:
  • has been clinically stable for the 24 months before screening; and,
  • is not anticipated by the participant's regular treating physician to have a sustained decline in kidney function by >10% over the following 12 months; and,
  • is not anticipated to need renal replacement therapy in the next 12 months; and,
  • does not have any other clinical, biochemical or familial feature at screening that suggests a decline in kidney function is anticipated in the next 12 months.

Exclusion criteria

Exclusion Criteria:

For Part A:

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug; or interfering with the interpretation of data.
  • History of of any type.
  • History of kidney disease or kidney abnormalities or less than (\<) 90 milliliters per minute per 1.73 square meters (mL/min/1.73m\^2) (based on the chronic kidney disease- Epidemiology Collaboration [CKD-EPI] 2021 eGFR equation) at screening.
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study drug and for the duration of study participation.
  • corrected (QTc)>450 milliseconds (msec)
  • Participation in this study would result in loss of blood or blood products in excess of 500 mL within 56 days
  • Current enrolment or past participation in an clinical trial in which an investigational medicinal product was administered within the following time periods prior to the first dosing day of the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product, whichever is longer
  • Exposure to more than 4 investigational medicinal products within 12 months prior to dosing
  • Significant allergy to humanized monoclonal antibodies
  • multiple or severe drug allergies, or severe post-treatment reactions (including, but not limited to, erythema multiforme major, linear Immunoglobulin A (IgA) dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis)
  • Pregnant or lactating female
  • Current or previous diagnosis of diabetes mellites (DM) (Type 1 or Type 2)
  • Glycosylated () >=48 millimoles per mole (mmol/mol) (>=6.5%) at screening
  • Bone fracture within 6 months prior to screening, or presence of a known unresolved or incompletely resolved fracture
  • Positive pre-clinical study drug/alcohol screen, including tetrahydrocannabinol
  • Positive (HIV) antibody test
  • Evidence of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, as determined by local diagnostic procedures
  • Evidence at screening of clinically significant hematological disorder (affecting hemoglobin, red blood cells [RBC], White blood cells [WBC] or ) or abnormal blood clotting parameters
  • Regular use of recreational drugs, including substances containing tetrahydrocannabinol
  • Participants who are unable to refrain from smoking, vaping or using other tobacco products during study visits or overnight stays
  • Poor peripheral venous access by visual inspection (intravenous [IV] administration cohort(s) only)
  • Average weekly intake of greater than (>) 14 United Kingdom (UK) units of alcohol. One UK unit is equivalent to 8 grams (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator [or medical monitor], contraindicates participation in the study
  • Use of any products intended to treat medical conditions that are not approved by the governing health authority in a given country or region (for example, herbal medicine, health supplements, traditional medicine, homeopathic remedies, etc.)
  • (ALT) >1.5x (ULN)
  • Total >1.5xULN; Participants with Gilbert's syndrome can be included with total bilirubin \<=3.0xULN as long as direct bilirubin is \<=1.0xULN
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • Presence of surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention
  • Positive antibody test result at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention

Part B:

  • Presence of active, clinically significant cardiovascular, respiratory, hepatic, gastrointestinal, endocrine (including, but not limited to, incompletely controlled secondary or tertiary hyperparathyroidism and clinically significant vitamin D deficiency), hematological (including, but not limited to, transfusion-dependent anemia), bone (including, but not limited to, osteoporosis), or neurological disorders, with the exception of ADPKD, capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug; or interfering with the interpretation of data
  • Clinically significant abnormal blood pressure (BP), that is, if the participant is not taking antihypertensive therapy: systolic BP >=160 millimeters of mercury (mmHg) and/or diastolic BP >=90mmHg; or If the participant is established on a stable regimen of antihypertensive drug(s): on-treatment systolic BP >=160 mmHg and/or diastolic BP >=90mmHg
  • Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of recurrence or disease for 3 years
  • Breast cancer within the past 10 years
  • Use of prescription and non-prescription drugs, including vitamins A, B, C, E, K, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study drug and for the duration of study participation. Paracetamol, at doses of \<=4 gram per 24 hour (g/24h) is permitted for use at any time during the study
  • to, or unwillingness to undergo, MRI scanning (e.g., presence of MRI-incompatible metal implant)
  • Congenital absence of one kidney
  • Kidney cyst interventions such as cyst aspiration or cyst fenestration within 12 weeks prior to screening and during the screening period, or such interventions planned or anticipated within the follow-up period
  • Acute symptomatic kidney cyst hemorrhage or infection within 12 weeks prior to screening
  • Evidence of current, chronic, or recurrent kidney or liver cyst infection
  • Estimated proteinuria >1g/24 hour at screening and/or pre-dose (day -7 to day -1)
  • Abnormal urinalysis suggestive of clinically significant glomerular disease or urinary tract infection
  • Presence of known clinically significant renal or hepatic calculi, or symptoms thereof, at screening
  • Treatment with tolvaptan within 6 months prior to screening
  • Presence of an incompletely healed wound at screening and/or planned surgical procedure that would occur during study.
  • Participation in this study would result in loss of blood or blood products in excess of 500 mL within 56 days
  • Current enrolment or past participation in an investigational clinical trial in which an investigational medicinal product was administered within the following time periods prior to the first dosing day of the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product, whichever is longer
  • Exposure to more than 4 investigational medicinal products within 12 months prior to dosing
  • Significant allergy to humanized monoclonal antibodies
  • Clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear Immunoglobulin A (IgA) dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis)
  • Pregnant or lactating female
  • Current or previous diagnosis of diabetes mellites (DM) (Type 1 or Type 2)
  • HbA1c >=48 millimoles per mole (mmol/mol) (>=6.5%) at screening
  • Bone fracture within 6 months prior to screening, or presence of a known unresolved or incompletely resolved fracture
  • Positive pre-clinical study drug/alcohol screen, including tetrahydrocannabinol
  • Positive HIV antibody test
  • Evidence of SARS-CoV-2 infection, as determined by local diagnostic procedures
  • Evidence at screening of clinically significant hematological disorder (affecting hemoglobin, RBC, WBC or platelets) or abnormal blood clotting parameters
  • Regular use of recreational drugs, including substances containing tetrahydrocannabinol
  • Participants who are unable to refrain from smoking, vaping or using other tobacco products during study visits or overnight stays
  • Poor peripheral venous access by visual inspection (IV administration cohort(s) only)
  • Average weekly intake of greater than (>) 14 UK units of alcohol. One UK unit is equivalent to 8 grams of alcohol: a half-pint (approximately240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator [or medical monitor], contraindicates participation in the study
  • Use of any products intended to treat medical conditions that are not approved by the governing health authority in a given country or region (for example, herbal medicine, health supplements, traditional medicine, homeopathic remedies, etc.)
  • Alanine transaminase (ALT) >1.5x Upper Limit of Normal (ULN)
  • Total bilirubin >1.5xULN; Participants with Gilbert's syndrome can be included with total bilirubin \<=3.0xULN as long as direct bilirubin is \<=1.0xULN
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • Presence of HBsAg and/or HBcAb at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention
  • QTc >450 milliseconds (msec) or QTc >480 msec for participants with bundle branch block
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    Part A: Cohort 1: Participants receiving GSK4771261 Dose level 1

    Healthy participants will be randomized to receive GSK4771261 Dose level 1.

    Drug: GSK4771261

  • Experimental
    Part A: Cohort 2 : Participants receiving GSK4771261 Dose level 2

    Healthy participants will be randomized to receive GSK4771261 Dose level 2.

    Drug: GSK4771261

  • Experimental
    Part A: Cohort 3: Participants receiving GSK4771261 Dose level 3

    Healthy participants will be randomized to receive GSK4771261 Dose level 3.

    Drug: GSK4771261

  • Experimental
    Part A: Cohort 4: Participants receiving GSK4771261 Dose level 4

    Healthy participants will be randomized to receive GSK4771261 Dose level 4.

    Drug: GSK4771261

  • Experimental
    Part A: Cohort 5: Participants receiving GSK4771261 Dose level 5

    Healthy participants will be randomized to receive GSK4771261 Dose level 5.

    Drug: GSK4771261

  • Experimental
    Part A: Cohort 6: Participants receiving GSK4771261 Dose level 6

    Healthy participants will be randomized to receive GSK4771261 Dose level 6.

    Drug: GSK4771261

  • Experimental
    Part A: Cohort 7 (optional): Participants receiving GSK4771261 Dose level 7

    Healthy participants will be randomized to receive GSK4771261 Dose level 7 as the recommendation of Dose escalation committee (DEC).

    Drug: GSK4771261

  • Experimental
    Part A: Cohort 8 (optional): Participants receiving GSK4771261 Dose level 8

    Healthy participants will be randomized to receive GSK4771261 Dose level 8, as per the recommendation from DEC.

    Drug: GSK4771261

  • Experimental
    Part B: Cohort 1: Participants receiving GSK4771261 Dose level 9

    Participant with Autosomal dominant polycystic kidney disease (ADPKD) will be randomized to receive GSK4771261 Dose level 9.

    Drug: GSK4771261

  • Experimental
    Part B: Cohort 2: Participants receiving GSK4771261 Dose level 10

    Participant with ADPKD will be randomized to receive GSK4771261 Dose level 10.

    Drug: GSK4771261

  • Experimental
    Part B: Cohort 3: Participants receiving GSK4771261 Dose level 11

    Participant with ADPKD will be randomized to receive GSK4771261 Dose level11.

    Drug: GSK4771261

  • Experimental
    Part B: Cohort 4 (optional): Participants receiving GSK4771261 Dose level 12

    Participant with ADPKD will be randomized to receive GSK4771261 Dose level 12 as the recommendation from DEC.

    Drug: GSK4771261

  • Experimental
    Part B: Cohort 5 (optional): Participants receiving GSK4771261 Dose level 13

    Participant with ADPKD will be randomized to receive GSK4771261 Dose level 13, as per the recommendation from DEC.

    Drug: GSK4771261

  • Placebo comparator
    Part A: Participants receiving Placebo matching GSK4771261

    Participants will receive placebo matching GSK4771261

    Drug: Placebo matching GSK4771261

  • Placebo comparator
    Part B: Participants receiving placebo matching GSK4771261

    Participants will receive placebo matching GSK4771261

    Drug: Placebo matching GSK4771261

Interventions

  • DrugGSK4771261

    GSK4771261 will be administered.

  • DrugPlacebo matching GSK4771261

    Placebo matching GSK4771261 will be administered.

07

What researchers measure

Primary outcomes

  1. Part A: Number of Participants with Adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: From Baseline (Day 1) up to Day 182 (End of study [EoS])

  2. Part B: Number of Participants with AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: From Baseline (Day 1) up to Day 182 (EoS)

  3. Part A: Number of Participants with Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria: results in death; is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant; abnormal pregnancy outcome (for example, spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy); is a suspected transmission of any infectious agent via an authorized medicinal product; or other situations.

    Time frame: From Baseline (Day 1) up to Day 182 (EoS)

  4. Part B: Number of Participants with SAEs

    An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria: results in death; is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant; abnormal pregnancy outcome (for example, spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy); is a suspected transmission of any infectious agent via an authorized medicinal product; or other situations

    Time frame: From Baseline (Day 1) up to Day 182 (EoS)

  5. Part A: Number of Participants with Clinically Significant Changes in Blood Laboratory Values

    Number of participants with clinically significant changes in blood laboratory values will be evaluated.

    Time frame: From Baseline (Day 1) up to Day 182 (EoS)

  6. Part B: Number of Participants with Clinically Significant Changes in Blood Laboratory Values

    Number of participants with clinically significant changes in blood laboratory values will be evaluated.

    Time frame: From Baseline (Day 1) up to Day 182 (EoS)

  7. Part A: Number of Participants with Clinically Significant Changes in Urine Laboratory Values

    Number of participants with clinically significant changes in Urine laboratory values will be evaluated.

    Time frame: From Baseline (Day 1) up to Day 182 (EoS)

  8. Part B: Number of Participants with Clinically Significant Changes in Urine Laboratory Values

    Number of participants with clinically significant changes in Urine laboratory values will be evaluated.

    Time frame: From Baseline (Day 1) up to Day 182 (EoS)

  9. Part A: Number of Participants with Clinically Significant Changes in Vital Signs

    Number of participants with clinically significant changes in vital signs (will be evaluated.

    Time frame: From Baseline (Day 1) up to Day 182 (EoS)

  10. Part B: Number of Participants with Clinically Significant Changes in Vital Signs

    Number of participants with clinically significant changes in vital signs will be evaluated.

    Time frame: From Baseline (Day 1) up to Day 182 (EoS)

  11. Part A: Number of Participants with Clinically Significant Changes in 12-lead Electrocardiogram (ECG)

    Number of participants with clinically significant changes in 12-lead ECG parameters will be evaluated.

    Time frame: From Baseline (Day 1) up to Day 182 (EoS)

  12. Part B: Number of Participants with Clinically Significant Changes in 12-lead ECG

    Number of participants with clinically significant changes in 12-lead ECG parameters will be evaluated.

    Time frame: From Baseline (Day 1) up to Day 182 (EoS)

Secondary outcomes

  1. Part A: Number of Participants with Anti-drug Antibodies for GSK4771261

    Number of participants with Anti-drug antibodies for GSK4771261 will be evaluated.

    Time frame: From Baseline (Day 1) up to Day 182 (EoS)

  2. Part B: Number of Participants with Anti-drug Antibodies for GSK4771261

    Number of participants with Anti-drug antibodies for GSK4771261 will be evaluated.

    Time frame: From Baseline (Day 1) up to Day 182 (EoS)

  3. Part A: Area under the concentration-time curve to the end of the dosing period AUC (0-tau) of GSK4771261

    Blood samples were collected to evaluate pharmacokinetics of GSK4771261.

    Time frame: Up to Day 182

  4. Part A: Area under the concentration-time curve to infinity AUC (0-inf) of GSK4771261

    Blood samples were collected to evaluate pharmacokinetics of GSK4771261.

    Time frame: Up to Day 182

  5. Part B: AUC (0-tau) of GSK4771261

    Blood samples were collected to evaluate pharmacokinetics of GSK4771261.

    Time frame: Up to Day 182

  6. Part B: AUC (0-inf) of GSK4771261

    Blood samples were collected to evaluate pharmacokinetics of GSK4771261.

    Time frame: Up to Day 182

  7. Part A: Maximum Plasma Concentration (Cmax) of GSK4771261

    Blood samples were collected to evaluate of GSK4771261.

    Time frame: Up to Day 182

  8. Part B: Cmax of GSK4771261

    Blood samples were collected to evaluate of GSK4771261.

    Time frame: Up to Day 182

08

Study locations

23 sites
  • GSK Investigational Site
    Rochester, Minnesota 55905, United States
  • GSK Investigational Site
    Brussels, 1200, Belgium
  • GSK Investigational Site
    Ghent, 9000, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    London, Ontario N6A 5A5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2C4, Canada
  • GSK Investigational Site
    Montreal, Quebec H4J 1C5, Canada
  • GSK Investigational Site
    Brest, 29200, France
  • GSK Investigational Site
    Paris, 75015, France
  • GSK Investigational Site
    Cologne, North Rhine-Westphalia 50937, Germany
  • GSK Investigational Site
    Lübeck, Schleswig-Holstein 23538, Germany
  • GSK Investigational Site
    Groningen, 9713 GZ, Netherlands
  • GSK Investigational Site
    Leiden, 2333 ZA, Netherlands
  • GSK Investigational Site
    Rotterdam, 3015 GD, Netherlands
  • GSK Investigational Site
    Barcelona, 08003, Spain
  • GSK Investigational Site
    Barcelona, 08025, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Cambridge, CB2 0GG, United Kingdom
  • GSK Investigational Site
    Exeter, EX2 5DW, United Kingdom
  • GSK Investigational Site
    London, NW3 2QG, United Kingdom
  • GSK Investigational Site
    Newcastle upon Tyne, NE1 4LP, United Kingdom
09

References and documents

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Jul 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Dec 16, 2024
StartActual
Dec 11, 2024
Primary completionEst.
Jul 23, 2027
CompletionEst.
Jul 23, 2027
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06734234
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 16, 2024
Start date
Dec 11, 2024
Primary completion
Jul 23, 2027 (estimated)
Completion
Jul 23, 2027 (estimated)
Last update
Jul 30, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion